Quarterly ResultMay 11, 2026, 04:08 PM
Aktis Oncology Q1 Net Loss $18.3M; Cash $538.5M; Pipeline Advances
AI Summary
Aktis Oncology reported a net loss of $18.3 million for Q1 2026, an increase from $15.0 million in Q1 2025, driven by higher operating expenses. The company's cash, cash equivalents, and marketable securities significantly increased to $538.5 million as of March 31, 2026, primarily due to $365.4 million gross proceeds from its January 2026 IPO, extending its operational runway into 2029. Aktis also advanced its clinical pipeline, initiating a Phase 1b trial for AKY-2519 in mCRPC and continuing enrollment for AKY-1189, with preliminary data for both expected in 2027 and Q1 2027, respectively.
Key Highlights
- Cash, cash equivalents, and marketable securities reached $538.5 million as of March 31, 2026.
- Net loss for Q1 2026 was $18.3 million, compared to $15.0 million in Q1 2025.
- Collaboration revenue increased to $3.2 million in Q1 2026 from $1.4 million in Q1 2025.
- Research and development expenses rose to $20.0 million in Q1 2026 from $15.9 million in Q1 2025.
- Completed an IPO in January 2026, generating approximately $365.4 million in gross proceeds.
- Initiated Phase 1b clinical trial of AKY-2519 in mCRPC, with preliminary data expected in 2027.
- Preliminary data from AKY-1189 Phase 1b trial expected in Q1 2027.
- Cash position expected to fund operations into 2029.